{"id":"W2622353385","doi":"10.1002/hon.2438_80","title":"MINIMAL RESIDUAL DISEASE AND OUTCOMES IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL) IN THE PHASE III GADOLIN TRIAL OF OBINUTUZUMAB AND BENDAMUSTINE VS BENDAMUSTINE","year":2017,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"","keywords":"Medicine; Bendamustine; Internal medicine; Minimal residual disease; Obinutuzumab; Population; Hazard ratio; Oncology; Gastroenterology; Follicular lymphoma; Surrogate endpoint; Bone marrow; Lymphoma; Confidence interval; Rituximab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001456374,0.000310599,0.001510649,0.0002212897,0.0001695465,0.00003221152,0.0004066903,0.0004410084,0.00009637802],"category_scores_gemma":[0.005654954,0.0001913976,0.0001266977,0.0001400149,0.001295439,0.00008773942,0.0004349358,0.0004662628,0.000005473276],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002148801,"about_ca_system_score_gemma":0.003574698,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005621826,"about_ca_topic_score_gemma":0.0003162928,"domain_scores_codex":[0.9967847,0.0004697109,0.0009715587,0.0006285187,0.0005193274,0.0006261521],"domain_scores_gemma":[0.9963655,0.002013141,0.0003819001,0.0008252182,0.00007747916,0.0003367349],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7686394,0.01902539,0.1006437,0.001761312,0.0004562355,0.06221125,0.003315956,0.00001276869,0.001626406,0.01104984,0.003006611,0.02825121],"study_design_scores_gemma":[0.8280876,0.01114225,0.150466,0.0002602211,0.0002985855,0.001724339,0.000678008,0.002839369,0.000219601,0.0009097825,0.003019294,0.0003548871],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9916311,0.0008330934,0.000003595653,0.005011829,0.0001230822,0.001531079,0.0000249144,0.0000220912,0.0008192024],"genre_scores_gemma":[0.9984435,0.0003172894,0.0003470945,0.0003934542,0.0001435899,0.0001642153,0.00002330275,0.00001994143,0.0001475918],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06048691,"threshold_uncertainty_score":0.7804967,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05161901287869262,"score_gpt":0.3889514008878156,"score_spread":0.337332388009123,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}